The study demonstrated sustained safety and efficacy of cyclosporine ophthalmic solution (Vevye) 0.1%, with many patients now entering their sixth refill cycle, according to the company.

The high-level analysis found in treatment follow-up that 82% of patients administered with TEPEZZA did not report needing any additional thyroid eye disease treatment for nearly 2 years.

The biotechnology company is developing the first protein-based artificial retina for patients with retinitis pigmentosa and age-related macular degeneration.

The novel therapy for dry eye is a cross-linked hyaluronic acid derivative cleared by the FDA.

The launch of the nutritional supplement follows a clinical trial that demonstrated healthy tear production and provided noticeable relief of dry eye symptoms in as little as 2 to 4 weeks.

The pachymeter is the most lightweight handheld product of its kind on the market, according to the company.

Catch up on what happened in optometry during the week of May 27-May 31.

The company’s initiatives include involvement with the Global Myopia Awareness Coalition and discounting blue light screen protectors and its pediatric eye care program, among others.

InflammaDry is a diagnostic test that detects elevated levels of MMP-9, an inflammatory marker consistently found in the tears of patients with DED.

The COAST and ShORe trials have a total of 1984 patients enrolled for the treatment of wet age-related macular degeneration.

Investigators found more cases than expected following tomography of 2007 eyes.

Lorraine Provencher, MD, reviews the NOVA trial which measured and validated the sensitivity of a novel VR-based wearable headset for visual field testing in glaucoma.

MyopiaX is a non-invasive, light-based treatment that uses a virtual reality headset to deliver treatment while patients engage with digital content.

The rabbit model found that the levels of the active metabolites were very comparable, whether or not eyes had received a prior installation of perfluorohexyloctane.

The study evaluated the effects of long-term, low-dose aspirin administration in over 3000 older adults.

North Bay Eye Associates transitions from traditional bowl perimeter to portable vision diagnostic and patient engagement system.